Navigation Links
PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
Date:9/3/2009

formulation lacking this adjuvant. Results showed that animals immunized with these formulations, whether supplemented with the adjuvant or not, were fully protected against challenge with 10(3 )median lethal doses of B. anthracis at day 21.

These preliminary data suggest that PharmAthene's 3G product prototype may be able to provide both faster time to immunity and significantly enhanced immunogenicity, indicating that the optimized formulation may be able to reduce the requirement for multiple vaccine doses, and simplify the immunization regimen for anthrax vaccines in the future.

Funding for this study was provided under a Challenge grant from the National Institutes of Health. The data from this study are intended to inform ongoing efforts in PharmAthene's 3G rPA program. In September 2008, PharmAthene was awarded a development contract from the National Institute of Allergy and Infectious Diseases (NIAID) of up to $83.9 million for the 3G rPA vaccine program, provided the government exercises all contract options at its sole discretion.

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the o
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... BASKING RIDGE, N.J. , Oct. 30, 2014 /PRNewswire/ ... announced that it will hold a conference call and ... 8:30 a.m. EST to discuss its third quarter 2014 ... access the conference call by dialing (888) 347-1165 for ... conference call will be webcast live under the investor ...
(Date:10/27/2014)... 27, 2014 The Italian ... exhibit and sell its artificial "lower limb", after ... patent.      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ... fighting, the definitive judgement has arrived: Roadrunnerfoot, the ... and accessible hi-tech prostheses with composite materials, has ...
Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... Spherix Incorporated (NASDAQ: SPEX ) – ... syndrome and atherosclerosis, and provider of technical and regulatory ... today announced that it has entered into definitive agreements ... stock and warrants to purchase shares of its common ...
... +49(0)69-2222-34066 France: +33(0)1-70-48-01-63 U.K.: +44(0)20-7660-0009 ... is 5634610; to view the webcast, log onto: ... March 13, 2012 - Annual press conference in Goettingen, Germany ... Germany April 24, 2012 - Publication of first-quarter ...
... A relatively fast, easy and inexpensive technique for ... self-assemble into one-, two- and even three-dimensional macroscopic ... researchers with the U.S. Department of Energy (DOE),s ... should enable more effective use of nanorods in ...
Cached Biology Technology:Spherix Announces Registered Direct Offering of $1.15 Million 2Spherix Announces Registered Direct Offering of $1.15 Million 3Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30% 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 3Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 4
(Date:10/31/2014)... In the war against Ebola one important hurdle has ... Researchers at the University of North Carolina at Chapel ... of mice that can be infected with Ebola and ... work, published in the current issue of Science ... and vaccines, which are desperately needed to curb the ...
(Date:10/31/2014)...  HITLAB SM , a healthcare innovation and ... HITLAB Innovators Summit SM on December 1, ... partner with the Clinton Foundation,s Health Matters Initiative, ... Business School Alumni Club of New ... Operations Research, bringing together leaders in healthcare and ...
(Date:10/30/2014)... in German . ... fellow humans to behave socially? This is one of ... theory. Previous studies assumed that it is almost impossible ... the Max Planck Institute for Evolutionary Biology have now ... on the cooperative behaviour of others. However, the possibilities ...
Breaking Biology News(10 mins):Improved mouse model will accelerate research on potential Ebola vaccines, treatments 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4
... This press release is available in German . ... pathogens and rogue cells in the body and put them out ... migrate from there into the thymus. Here, they mature and differentiate ... Institute of Immunobiology and Epigenetics in Freiburg have now succeeded for ...
... Deepwater Horizon oil spill in the Gulf of Mexico in April ... fisheries. A new study published in the Canadian Journal of ... 7 years this oil spill could have a $US8.7 billion impact ... in revenue, profit, and wages, and close to 22 000 jobs ...
... The understanding of diseases such as Parkinson,s and Alzheimer,s ... technology at which will enable cell analysis using automated ... School of Information Communication Technology and the Eskitis Institute ... the automated identification, separation and analysis of cells as ...
Cached Biology News:Live from the thymus: T-cells on the move 2Live from the thymus: T-cells on the move 3
... DNA Polymerase I Large (Klenow) Fragment, Exonuclease ... lacks both the 5´→3´ and the 3´→5´ ... DNA Polymerase I (1,2). It is used ... strand displacement amplification (5). Klenow Fragment, Exonuclease ...
SMVT (N-14)...
...
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is a ... effective in inhibiting retroviral activity. Immunogen: ... Specificity: The specificity of the ... of the moles of ddC to moles of ...
Biology Products: